版本:
中国

BRIEF-Ionis Pharmaceuticals reports phase 1/2 clinical study results with AKCEA-ANGPTL3-L

May 25 Ionis Pharmaceuticals Inc

* Reports phase 1/2 clinical study results with AKCEA-ANGPTL3-L

* Says AKCEA-ANGPTL3-L was well tolerated with no serious adverse events Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐